Screen LibraryHormone replacement therapy and cardiovascular disease
Saved in:
| Group Author: | |
|---|---|
| Published: |
Parthenon Pub. Group,
|
| Publisher Address: | New York |
| Publication Dates: | c2001. |
| Literature type: | Book |
| Language: | English |
| Series: |
Controversial issues in climacteric medicine series |
| Subjects: | |
| Carrier Form: | viii, 188 p.: ill. ; 26 cm. |
| ISBN: | 1842140388 (alk. paper) |
| Index Number: | R711 |
| CLC: |
R711.51-532 R541-532 R459.1-532 |
| Call Number: | R541-532/H812/2000 |
| Contents: |
The presentations given during the Expert Workshop on Hormone Replacement Therapy and Cardiovascular Disease, organized by the International Memopause Society, and held in London on October 13-16, 2000. Includes bibliographical references and index. Ch. 1. Trends in mortality rates for cardiovascular and cerebrovascular diseases in developed countries -- Ch. 2. Cardiovascular aging in women and men in the absence of clinical disease -- Ch. 3. Lipid metabolism -- Ch. 4. Diabetes, obesity and cardiovascular disease -- Ch. 5. Endothelial function in hypertension: role of gender -- Ch. 6. Venous thromboembolism and hormone replacement therapy -- Ch. 7. Acute coronary syndromes in women -- Ch. 8. Estrogen receptor-β and women's health -- Ch. 9. Molecular biology of selective estrogen receptor modulators -- Ch. 10. The estrogen receptor knock-out mouse model -- Ch. 11. Sex steroids in the cardiovascular system: molecular mechanisms of action -- Ch. 12. Progestins and the cardiovascular system -- Ch. 13. Sex steroids and the cardiovascular system in vivo: actions in animal models -- Ch. 14. Sex steroids and the cardiovascular system in vivo: actions in humans -- Ch. 15. Sex steroids and blood coagulation -- Ch. 16. Lipoprotein-associated estrogen: the role of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein -- Ch. 17. Cardiovascular effects of hormone replacement therapy: what factors may influence risk? -- Ch. 18. Effects of transdermal hormone replacement therapy on cardiovascular outcomes: epidemiological evidence -- Ch. 19. Pulsed estrogen therapy: Aerodiol® -- Ch. 20. Cardiovascular effects of raloxifene: data from preclinical studies and clinical trials in postmenopausal women -- Ch. 21. Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial®) -- Ch. 22. Hormone replacement therapy and myocardial infarction -- Ch. 23. Hormonal replacement therapy, venous thromboembolism and stroke. |